D Pharm Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
HBL Hadasit Bio Holding Ltd's Thrombotech Ltd To Merge With D-Pharm Ltd.
HBL Hadasit Bio Holding Ltd announced that Thrombotech, a portfolio company which Hadasit holds a 24.8% stake in, signed a merger agreement with D-Pharm, a clinical stage, technology-driven biopharmaceutical company developing products for treatment of CNS disorders. Both parties have agreed on the terms and conditions of the merger, and the closing is subject to various approvals and regulatory permits. Upon completion of the transaction, Hadasit Bio-Holdings will hold approximately 15% of D- Pharm. Additionally, D-Pharm will issue rights for a sum of 11.5 million NIS (~USD3 million), of which about NIS5.4 million has been committed to by Clal Biotechnology.
Latest Key Developments in Biotechnology
- BioSpecifics Technologies Corp announces FDA approval of XIAFLEX for treatment of peyronie's disease
- Xencor Inc announces closing of initial public offering
- Genmab reaches milestone from Janssen and raises FY 2013 financial guidance
- Genmab says milestone from Lundbeck puts revenue at top end of FY 2013 outlook range
- Share this
- Digg this